A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy

Kinoshita S, Colby KA, Kruse F (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Cornea Lippincott, Williams & Wilkins

Book Volume: 40

Pages Range: 1225-1228

Journal Issue: 10

DOI: 10.1097/ICO.0000000000002642

Abstract

ABSTRACT: The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.

Authors with CRIS profile

Friedrich Kruse Lehrstuhl für Augenheilkunde

Involved external institutions

Kyoto Prefectural University of Medicine / 京都府立医科大学 JP Japan (JP) New York University (NYU) US United States (USA) (US)

How to cite

APA:

Kinoshita, S., Colby, K.A., & Kruse, F. (2021). A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy. Cornea, 40(10), 1225-1228. https://doi.org/10.1097/ICO.0000000000002642

MLA:

Kinoshita, Shigeru, Kathryn A. Colby, and Friedrich Kruse. "A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy." Cornea 40.10 (2021): 1225-1228.

BibTeX: Download